Cryoport, Inc.

CYRX
About the company

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry.

Country: United StatesPrice: $19.89Market Cap: $1.0B

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

4 / 12

NEUTRAL / FAIL

Median fair value

$21.23

+6.7% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Graham, Buffett, Lynch +1 more object

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2199 (Top 71%)NEUTRALFAILNEUTRALNEUTRALFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-11.6%+6.3%N/AN/AN/AN/AN/A+37.6%N/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: -18.3x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities2.04
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-18.3x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0023; #424/4210 (top 10.1%)
    ✓AsnessTop 30% of eligible cross-section
  • Valuation models67% pass✓ 2✗ 1▾

    Models split on CYRX at $19.89 — fair values range $17.82–$31.88

    Graham fair value$17.82
    ✗Graham-11.6% margin vs $19.89
    Buffett fair value$21.23
    ✓Buffett+6.3% margin vs $19.89
    Pabrai fair value$31.88
    ✓Pabrai+37.6% margin vs $19.89

Where It Falls Short

  • Growth0% pass✓ 3✗ 10▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 14.2x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -3.8% vs Rev: 1.1%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.46 (2010) -> $1.40 (2025)
    ✓DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-7.1%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 44.7% -> 47.1%, operating margin -59.6% -> -20.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR17.5%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts0% pass✗ 13▾

    Split decision: 12 FAIL · 4 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (2/9)✗LynchFAIL (2/7)✗GreenblattRank #2199•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (4/11)•MungerNEUTRAL (3/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1133/2370 (Top 47.8%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Profitability6% pass✓ 7✗ 28▾

    15 of 16 flag CYRX's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)1/17 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/17 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-16.6%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-20.9% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$89.6M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 14.2x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-8.5%
    ✗Lynch> 15%
    EBIT / Enterprise Value-4.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-4.9%, ROC=-40.0%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets10.24%
    ✓PiotroskiROA > 0
    ROA Change YoY-16.31% -> 10.24% (delta: +26.55%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-1.12%, ROA=10.24%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY44.4% -> 47.1%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-18.3%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-8.5%
    ✗Dreman> 12%
    Margin of SafetyP/E=14.2x, P/B=2.0x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-11.1% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/16 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-20.0%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-8.5%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-59.6% (2023) -> -20.9% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 44.7% -> 47.1%, operating margin -59.6% -> -20.9%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-4.10%; #3789/6340 (top 59.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+12.02%; #2656/3702 (top 71.7%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-8.54%; #3352/5226 (top 64.1%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1186; #3687/5884 (top 62.7%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Valuation15% pass✓ 6✗ 22▾

    11 of 13 flag CYRX's valuation — Graham, Lynch, Greenblatt +8 more

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio2.0x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 14.2x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-4.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-4.9%, ROC=-40.0%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS14.2x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share2.0x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=14.2x, OE Yield=9.0%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=14.2x, FCF Yield=-2.5%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=14.2x, P/B=2.0x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low357% of trailing low ($5.57)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-4.10%; #3789/6340 (top 59.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4800; #2963/6449 (top 45.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS14.2x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share2.90x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+4.9%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1910; #3823/5247 (top 72.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-1.87%; #2750/4519 (top 60.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+105.69%; #304/6202 (top 4.9%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Cash Flow20% pass✓ 2✗ 10▾

    8 of 10 flag CYRX's cash flow — Lynch, Piotroski, Dreman +5 more

    Free Cash Flow Proxy$89.6M
    ✓BuffettPositive and growing
    FCF Positive and Growing$-18.8M
    ✗LynchPositive and growing
    Operating Cash Flow$-8.6M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-1.12%, ROA=10.24%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=14.2x, FCF Yield=-2.5%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/16 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-1.9%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency1/16 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-18.8M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-1.87%; #2750/4519 (top 60.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag CYRX's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio2.04
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-7.3%
    ✗Buffett> 10%
    ROIC - WACC-17.3%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-40.0%
    ✗Greenblatt> 25%
    Current Ratio Change YoY5.29 -> 2.17
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.22x -> 0.23x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities2.04
    ✓Dreman> 1.5
    Return on Invested Capital-6.3%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-9.2%; FY2024: ROIC=-16.4%; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest -16.4%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Small Cap($1.0B)
Revenue: $176.2M+12.4% YoY
Net Income: $78.3M+168.2% YoY

Financial Snapshot

Operating Margin-20.9%
Return on Equity15.6%
Debt / Equity--
Current Ratio2.17
EPS (Diluted)$1.40
Buybacks (1y)$10.0M
Shares Retired0.1% / −1.8% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Retired 0.1% of shares last year, 1.8% issued over two.

Buybacks
$10.0M
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-05
FY 2024
Sources
  • 10-K · 2025-03-07
FY 2023
Sources
  • 10-K · 2024-03-13
FY 2022
Sources
  • 10-K · 2023-02-28
FY 2021
Sources
  • 10-K · 2022-02-28
Market Cap$1.0Bcurrent------$474.1Mest.$376.3Mest.$710.7Mest.$1.1Best.$1.7Best.
Revenue$192.4M↑1%$50.2M↑14%$49.0M↑8%$47.8M↑16%$176.2M↑12%$156.8M↓7%$168.7M↓29%$237.3M↑7%$222.6M
Operating Income-$38.5M↑10%-$8.8M↑11%-$10.0M↓4%-$9.6M↓1%-$36.8M↑70%-$121.7M↓21%-$100.5M↓215%-$31.9M↓79%-$17.8M
Net Income-$41.3M↓161%-$10.9M↓56%-$8.3M↓108%-$10.5M↑12%$78.3M↑168%-$114.8M↓15%-$99.6M↓167%-$37.3M↑86%-$275.5M
EPS (Diluted)--$-0.25↓39%$-0.20↓110%$-0.25↑11%$1.40↑156%$-2.49↓13%$-2.21↓138%$-0.93↑85%$-6.19
Gross Margin46.9%↑1%47.5%↓2%46.6%↓1%45.8%↑1%47.1%↑6%44.4%↓1%44.7%↑2%43.8%↑1%43.4%
Operating Margin-20.0%↑11%-17.5%↑22%-20.5%↑3%-20.1%↑13%-20.9%↑73%-77.6%↓30%-59.6%↓343%-13.4%↓68%-8.0%
ROE-8.5%↓165%———15.6%↑155%-28.6%↓40%-20.4%↓203%-6.7%↑84%-42.9%
Total Debt$1.1M↓99%$1.1M↓99%$1.1M↓99%$1.2M↓99%--$184.1M↓51%$378.7M↓7%$406.8M↑1%$404.2M
Shareholders' Equity$483.5M↓6%$483.5M↓6%$490.7M↓5%$495.0M↑24%$502.6M↑25%$401.9M↓18%$489.0M↓12%$555.8M↓13%$641.8M
Current Ratio2.04↓87%2.04↓87%2.08↓87%2.09↓62%2.17↓59%5.29↓55%11.73↓21%14.79↓9%16.26
Debt / Equity0.00↓99%0.00↓99%0.00↓99%0.00↓99%—0.46↓41%0.77↑6%0.73↑16%0.63
Operating Cash Flow$11.0M↑173%$5.2M↑138%$1.1M↑115%$3.7M↑186%-$8.6M↑47%-$16.3M↓2056%-$757.0K↑59%-$1.9M↓123%$8.1M
Free Cash Flow-$18.8M↑40%-$40.0K↑97%-$8.0M↑32%-$6.2M↑17%-$25.0M↑25%-$33.6M↑15%-$39.5M↓65%-$24.0M↓52%-$15.8M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

CYRX vs Peers — Financial Grading

Revenue$176.2MBottom 25%
Net Income$78.3MMedian
ROE15.6%Top 25%
D/E—
Op. Margin-20.9%Bottom 25%
Curr. Ratio2.17Median
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11